MIDTERM RESULTS OF THE OBSERVATIONAL NON-INTERVENTIONAL CLINICAL STUDY "EVALUATION OF THE EFFECTIVENESS OF THE CARNITINE OROTATE AND BIPHENYL DIMETHYL DICARBOXYLATE COMPLEX IN THE PATHOGENETIC THERAPY OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE: A PROSP
Introduction. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a widespread pathology requiring effective treatment approaches. One promising direction is the use of a complex of carnitine orotate and biphenyl dimethyl dicarboxylate (COC and BDD), which possess antioxidant and hepatoprotective properties.
Materials and methods. As part of the observational, non-interventional, prospective cohort study KASVM-01 [NCT06078722], the impact of COC and BDD on the progression of MAFLD in patients in the Republic of Kazakhstan was investigated. From February 2023 to July 2024, a total of 121 participants from Almaty and Almaty Region were enrolled in the study and received COC and BDD. The observation period lasted 12 months, with an interim analysis conducted on 78 participants who completed a 24-week treatment course. Anthropometric parameters (BMI, waist circumference), liver steatosis, and fibrosis levels measured via transient elastography (FibroScan) with CAP, ALT, AST, total cholesterol, triglycerides, and FIB-4 (a non-invasive fibrosis marker) were assessed at baseline and after completing 24 weeks of therapy with COC and BDD.
Results. The interim analysis revealed a statistically significant reduction in ALT levels (from 32.4 to 20.1 U/mL, p<0.001), triglycerides (from 1.4 to 1.3 mmol/L, p=0.007), steatosis grade (from 304 to 283 dB/m, p<0.001), and fibrosis level (from 6.5 to 6.0 kPa, p=0.022). The prevalence of severe steatosis (S3) decreased from 52.7% to 45.7%, whereas mild steatosis (S1, S0) increased to 21.4% and 10%, respectively (p=0.001). The proportion of patients with F3 fibrosis declined from 8.1% to 1.4%, while F2 fibrosis decreased from 27% to 21.4% (p=0.022), indicating an improvement in fibrosis markers. During the observation period, BMI decreased (from 30.4 to 29.8 kg/m²), although the changes were not statistically significant (p=0.214). No significant changes were observed in total cholesterol and FIB-4 levels.
Conclusion. The interim analysis confirmed the effectiveness of COC and BDD in the treatment of MAFLD, demonstrating improvements in biochemical parameters as well as regression of liver steatosis, and fibrosis. Further research and validation of these findings in later stages of observation are necessary to assess the final efficacy and long-term safety of the therapy.
Number of Views: 519
Category of articles:
Original article
Bibliography link
Jumabayeva A., Kaibullayeva J., Kaisina A., Nugmanova B., Zhumadilova Z., Botabayeva A., Ualiyeva A., Pashimov M., Kambarova G., Omarova K., Muratbekova A., Balabek A., Yergaliyeva A., Reshidova T., Saktagan A., Kassymova T., Mutaliyeva G., Anuar A., Kudaibergenova Sh. Midterm results of the observational non-interventional clinical study "Evaluation of the effectiveness of the carnitine orotate and biphenyl dimethyl dicarboxylate complex in the pathogenetic therapy of metabolic-associated fatty liver disease: a prospective cohort study» // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (1), pp. 7-14. doi 10.34689/SH.2025.27.1.001Related publications:
EPIDEMIOLOGY, RESOURCE DISTRIBUTION, AND MANAGEMENT CHALLENGES OF CHRONIC HEART FAILURE IN KAZAKHSTAN: A NATIONAL RETROSPECTIVE ANALYSIS
PREVALENCE OF POLYMORPHISMS IN WARFARIN METABOLISM-RELATED GENES AMONG THE KAZAKH POPULATION
NEUROLOGICAL COMPLICATIONS IN EXTRACORPOREAL MEMBRANE OXYGENATION: RISK FACTORS FOR THE DEVELOPMENT OF ACUTE CEREBROVASCULAR EVENTS
THE EFFECT OF REPAGLINIDE AND METFORMIN ON EXTERNAL RESPIRATORY FUNCTION IN PATIENTS WITH DIABETES AND ISCHEMIC HEART DISEASE ASSOCIATED WITH OBESITY
RETROSPECTIVE ANALYSIS OF PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF THE LOWER EXTREMITY ARTERIES IN THE ABAI REGION OF THE REPUBLIC OF KAZAKHSTAN